Skip to main content
x
Dartmouth-Hitchcock logo
Summer Flowers In This Section

Cerebrovascular Disease and Stroke Program

Cerebrovascular diseases are disorders of blood vessels and brain arteries that supply blood to the brain. Cerebrovascular diseases can cause common conditions, such as aneurysms, dementia, and strokes, affecting more than 62 million people in the United States.

This website provides information about prevention, recognizing the warning signs of a stroke, and the Cerebrovascular Disease and Stroke Program's methods to diagnose and treat cerebrovascular diseases. We suggest the following links to get you started:

Stroke Support Group

The Stroke Support Group now includes the former Arteriovenous Malformation and Aneurysm Support Group.

This support group meets on the first Friday of every even-numbered month from 10:00 to 11:30 am. Stroke and Arteriovenous Malformation (AVM) survivors, family members, and caregivers are welcome to share their experiences and gain support, education, and encouragement from others. For more information, please contact Sarah Murphy, Administrative Assistant at 603-653-1295 or email Sarah.L.Murphy@hitchcock.org; or Shawna Malynowski, Stroke Program Coordinator at 603-653-1117 or email Shawna-Markie.S.Malynowski@hitchcock.org.

This group meets at the Aging Resource Center located at 46 Centerra Parkway, second floor, in Lebanon, NH.

About the program

The goal of the Cerebrovascular Disease and Stroke program is to provide the highest quality, evidenced-based care for patients and families dealing with stroke, transient ischemic attack, and other cerebrovascular conditions, including brain aneurysms and vascular malformations.

Specific goals for our program include:

  • Becoming recognized as a comprehensive center for cerebrovascular care and the regional "hub" of a stroke network that shares resources and improves access to high-quality and cost-effective care for patients in our region
  • Participating in the best clinical trials in our field
  • Bringing relevant basic science and translational research to DHMC
  • Being a resource for the education of residents, medical students, nurses, primary care providers, and other specialists

The Cerebrovascular Disease and Stroke Program members strive to meet the needs of stroke patients and their caregivers across the entire continuum of care. We aim to decrease the occurrence of stroke and its complications in the population we serve and advance the field of Cerebrovascular disease care.

Program certifications and awards

Joint Commission Certified Primary Stroke Center

The Joint Commission National Quality Approval The Stroke Program at Dartmouth-Hitchcock Medical Center has attained advanced certification by The Joint Commission. This means that this program:

  • Provides the next generation of stroke care
  • Has met and seeks to maintain The Joint Commission’s high standards in providing stroke care

The Joint Commission is an independent, not-for-profit organization that accredits and certifies nearly 21,000 health care organization and programs nationwide.

American Heart Association/American Stroke Association’s Get With The Guidelines®-Stroke Gold Plus Achievement Award

2020 Get With The Guidelines Stroke Gold Plus Achievement Award logo This award is given to health care facilities that meet specific quality achievement measures for the diagnosis and treatment of stroke patients at a set level for a designated period. These measures include evaluation of the proper use of medications and other stroke treatments aligned with the most up-to-date, evidence-based guidelines with the goal of speeding recovery and reducing death and disability for stroke patients. Before discharge, patients should also receive education on managing their health, get a follow-up visit scheduled, as well as other care transition interventions.

American Heart Association/American Stroke Association’s Target: Stroke Elite Plus Honor Roll

To qualify for this recognition, hospitals must meet quality measures developed to reduce the time between the patient’s arrival at the hospital and treatment with the clot-buster tissue plasminogen activator, or tPA, the only drug approved by the U.S. Food and Drug Administration to treat ischemic stroke.

Contact Us

0